Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others

June 02 20:34 2021
Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others

Medulloblastoma Pipeline

Medulloblastoma is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Signs and symptoms of medulloblastoma may include headaches, nausea, vomiting, tiredness, dizziness, double vision, poor coordination and unsteady walk. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests.

DelveInsight’s, “Medulloblastoma Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Request for free sample report:


Some of Medulloblastoma Companies are:

  • Oncurious
  • Y-mAbs Therapeutics
  • Senhwa Biosciences
  • Sun Pharmaceutical Industries
  • Roche
  • Nelum
  • WPD Pharmaceuticals
  • Midatech
  • Kintara Therapeutics
  • VBI Vaccines
  • Oncoheroes Biosciences
  • And Many Others


Request for free sample report:


DelveInsight’s Medulloblastoma report covers around 12+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Some of Medulloblastoma therapies are:

  • TB-403
  • Omburtamab-Lu-177
  • Silmitasertib
  • Sonidegib
  • Vismodegib
  • NLM 001
  • WP1066
  • Panobinostat
  • Dianhydrogalactitol
  • VBI 1901
  • 2HIT medulloblastoma
  • And Many Others


Request for free sample report:


Current Medulloblastoma Treatment Scenario and Medulloblastoma Emerging Therapies:

  • How many companies are developing Medulloblastoma drugs?
  • How many Medulloblastoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medulloblastoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Medulloblastoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Medulloblastoma and their status?
  • What are the key designations that have been granted to the emerging drugs?


Table of Contents:


Executive Summary

Medulloblastoma: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Medulloblastoma – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Medulloblastoma Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Drug name: Company name

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Vismodegib: Roche

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

• Comparative Analysis

Omburtamab-Lu-177: Y-mAbs Therapeutics

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

• Comparative Analysis

Dianhydrogalactitol: Kintara Therapeutics

Drug profiles in the detailed report…..

Inactive Products

Medulloblastoma Key Companies

Medulloblastoma Key Products

Medulloblastoma- Unmet Needs

Medulloblastoma- Market Drivers and Barriers

Medulloblastoma- Future Perspectives and Conclusion

Medulloblastoma Analyst Views

Medulloblastoma Key Companies


Request for Detailed TOC:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States